Provision of Assay Kits for SCID & SMA In-Service Evaluations - EONIS-Q Revvity
NHS EnglandcontractContracts Finder ↗Ref CF-3430100D0O000000rwimUAASME suitableVCSE suitablecomplete
Estimated value
£4.1m
Awarded value
£4.1m
Awarded 25 Mar 2026
Suppliers
1
Lots
1
1 awarded
Published
12 Mar 2026
Deadline 12 Mar 2026
Description
EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).
Scope
- Reference
- CF-3430100D0O000000rwimUAA
- Total value
- £4,074,117 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Mar 2026 to 30 Mar 2029
- CPV classifications
- 33100000
- Particular suitability
- Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)
Submission & procedure
- Submission deadline
- 12 Mar 2026, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£4.1m
Award date
25 Mar 2026
Contract start
31 Mar 2026
Contract end
30 Mar 2029
Awarded to